SLC2A1 and ovarian cancer: An orally active selective inhibitor of glucose transporter 1 (GLUT1). It suppresses glycolysis, including stress-regulated glycolysis, in ovarian cancer cells and also hinders their adhesion-dependent and -independent growth. Finally, it inhibits the growth of RB1-positive triple-negative breast cancer.